Journal
AMERICAN JOURNAL OF ROENTGENOLOGY
Volume 213, Issue 2, Pages 309-317Publisher
AMER ROENTGEN RAY SOC
DOI: 10.2214/AJR.19.21123
Keywords
Lu-177-DOTATATE; lutetium 177; neuroendocrine tumors; peptide receptor radionuclide therapy
Funding
- Advanced Accelerator Applications
- Endocyte Inc.
- GE Healthcare
- Novartis company
Ask authors/readers for more resources
OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of patients with neuroendocrine tumors. CONCLUSION. Most well differentiated and some moderately and poorly differentiated neuroendocrine tumors express large numbers of somatostatin receptors on their cell surfaces. PRRT targets these cells with Lu-177-DOTATATE, which is a medium-energy beta emitter. Since this agent received U.S. Food and Drug Administration approval in 2018, tremendous effort has been exerted at institutions throughout the United States toward proper implementation of this promising therapy. This review summarizes clinical implementation of PRRT and its impact on patient care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available